Psychiatric disorders are among the top causes of disability and morbidity worldwide. Despite the rapid progression of psychiatric pharmaceuticals, there are still significant challenges for the effective management of psychiatric disorders. The blood–brain barrier significantly restricts the access of psychiatric drugs to target cells in the brain tissues. The use of drug-loaded nanoparticles (NPs) is now well considered a viable option for improving the treatment efficacy of currently available drugs and reducing adverse effects. This review summarizes the recent advances and provides the unique characteristics of NP-based formulations as a promising avenue for targeted drug delivery for psychiatric disorders.Cite this article as: Shafiee-Kandjani AR, Hamidi S, Azarfarin M, Valipour F, Salatin S. Nano-assisted drug delivery systems for the improved treatment of neuropsychiatric disorders. Neuropsychiatr Invest. 2025, 63, 0058, doi: 10.5152/ NeuropsychiatricInvest.2025.24058.
Benzodiazepines (BZDs) are a class of prescription medications widely used for their anxiolytic, hypnotic, and muscle relaxant properties. Prolonged use of BZDs has been shown to increase the risk of abuse, dependence, and relapse in patients. Elderly people are particularly more vulnerable to the effects of BZDs due to altered pharmacokinetics and pharmacodynamics, along with drug interactions resulting from polypharmacy. These processes initiated by BZDs may trigger the onset of cognitive pathologies such as Alzheimer’s disease (AD). The present study focused on the relationship between BZD use and its contribution to neuroinflammation in AD. Moreover, it summarized some studies evaluating the effect of BZDs in the AD population.